Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday.
President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment.
Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances."
AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added.
Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
22 minutes ago
- The Hindu
India will continue to buy Russian oil, government sources tell NYT
India will keep purchasing oil from Russia despite U.S. President Donald Trump's threats of penalties, two Government sources told The New York Times, not wishing to be identified due to the sensitivity of the matter. "These are long-term oil contracts," one of the sources said. "It is not so simple to just stop buying overnight." Mr. Trump last month indicated in a Truth Social post that India would face additional penalties for purchases of Russian arms and oil. On Friday (August 1, 2025), Mr. Trump told reporters that he had heard that India would no longer be buying oil from Russia. Soured relations: The Hindu editorial on Trump's 25% tariff, 'penalty' The New York Times on Saturday (August 2, 2025) quoted two unnamed senior Indian officials as saying there had been no change in Indian government policy, with one official saying the government had "not given any direction to oil companies" to cut back imports from Russia. Reuters reported this week that Indian state refiners stopped buying Russian oil in the past week, following a narrowing of discounts in July. "On our energy sourcing requirements ... we look at what is there available in the markets, what is there on offer, and also what is the prevailing global situation or circumstances," Foreign Ministry spokesperson Randhir Jaiswal told reporters during a regular briefing on Friday. Mr. Jaiswal added that India has a "steady and time-tested partnership" with Russia, and that New Delhi's relations with various countries stand on their own merit and should not be seen from the prism of a third country. The White House in Washington did not immediately respond to requests for comment. Indian refiners are pulling back from Russian crude as discounts shrink to their lowest since 2022, when Western sanctions were first imposed on Moscow, due to lower Russian exports and steady demand, sources said earlier this week. The country's state refiners — Indian Oil Corp, Hindustan Petroleum Corp, Bharat Petroleum Corp and Mangalore Refinery Petrochemical Ltd — have not sought Russian crude in the past week or so, four sources familiar with the refiners' purchase plans told Reuters. India's top oil supplier On July 14, Mr. Trump threatened 100% tariffs on countries that buy Russian oil unless Moscow reaches a major peace deal with Ukraine. Russia is the top supplier to India, responsible for about 35% of India's overall supplies. Russia continued to be the top oil supplier to India during the first six months of 2025, accounting for about 35% of India's overall supplies, followed by Iraq, Saudi Arabia and the United Arab Emirates. India, the world's third-largest oil importer and consumer, received about 1.75 million barrels per day of Russian oil in January-June this year, up 1% from a year ago, according to data provided to Reuters by sources. Nayara Energy, a major buyer of Russian oil, was recently sanctioned by the European Union as the refinery is majority-owned by Russian entities, including oil major Rosneft . Last month, Reuters reported that Nayara's chief executive had resigned after the imposition of EU sanctions and company veteran Sergey Denisov had been appointed as CEO. Three vessels laden with oil products from Nayara Energy have yet to discharge their cargoes, hindered by the new EU sanctions on the Russia-backed refiner, Reuters reported late last month.
Hindustan Times
22 minutes ago
- Hindustan Times
Ukraine hits military targets and pipeline in Russia
Ukraine said Saturday it hit military targets and a gas pipeline in drone attacks in Russia, where local authorities said three people were killed and two others wounded. President of Ukraine Volodymyr Zelenskyy attends the parliament session in Kyiv, Ukraine Thursday, July 17, 2025. (AP Photo/Vadym Sarakhan)(AP) Ukraine's SBU security service said the strikes, carried out Friday night by long-distance drones, hit a military airfield in the southwestern town of Primorsko-Akhtarsk. They caused a fire in an areas where Iranian-built Shahed drones -- relied on by Russia to attack Ukraine -- were stored, the SBU said. It said the strikes also hit a company, Elektropribor, in Russia's southern Penza region, which it said "works for the Russian military-industrial complex", making military digital networks, aviation devices, armoured vehicles and ships. The governor for the Penza region, Oleg Melnichenko, said on Telegram that one woman had been killed and two other people were wounded in that attack. Russia's defence ministry said its air-defence systems had destroyed 112 Ukrainian drones over Russian territory -- 34 over the Rostov region -- in a nearly nine-hour period, from Friday night to Saturday morning. An elderly man was killed inside a house that caught fire due to falling drone debris in the Samara region, governor Vyacheslav Fedorishchev posted on Telegram. In the Rostov region, a guard at an industrial facility was killed after a drone attack and a fire in one of the site's buildings, acting Rostov governor Yuri Sliusar said. "The military repelled a massive air attack during the night," destroying drones over seven districts, Sliusar posted on Telegram. Heavy use of drones Ukraine has regularly used drones to hit targets inside Russia as it fights back against Moscow's full-scale invasion, launched in February 2022. Russia, too, has increasingly deployed the unmanned aerial devices as part of its offensive. An AFP analysis published on Friday showed that Russia's forces in July launched an unprecedented number of drones, 6,297 of them. The figure included decoy drones sent into Ukraine's skies in efforts to saturate the country's air-defence systems. In Ukraine's central-eastern Dnipropetrovsk region, Russian drone attacks Friday night wounded three people, governor Sergiy Lysak wrote on Telegram. Several buildings, homes and cars were damaged, he said. Russian forces have claimed advances in Dnipropetrovsk, recently announcing the capture of two villages there, part of Moscow's accelerated capture of territory in July, according to AFP's analysis of data from the US-based Institute for the Study of War (ISW). Kyiv denies any Russian presence in the Dnipropetrovsk area. Russian President Vladimir Putin, who has consistently rejected calls for a ceasefire in the more than three-year conflict, said Friday that he wanted peace but that his demands for ending Moscow's military offensive were "unchanged". Those demands include that Ukraine abandon territory and end ambitions to join NATO. Ukrainian President Volodymyr Zelensky, meanwhile, said only Putin could end the war and renewed his call for a meeting between the two leaders. "The United States has proposed this. Ukraine has supported it. What is needed is Russia's readiness," he wrote on X.
Time of India
22 minutes ago
- Time of India
Humanoid robot roams NYC, tries on sneakers, grabs hot dogs, and amazes New Yorkers
In July 2025, KraneShares introduced KOID, a $100,000 humanoid robot, in Midtown NYC to promote their Global Humanoid and Embodied Intelligence Index ETF. The stunt involved KOID walking down Fifth Avenue, interacting with people, and even trying on sneakers at a Hoka store, generating mixed reactions from amazement to fear. People in Midtown, New York City (NYC), were left amazed and flabbergasted after the humanoid marched through Midtown. Tired of too many ads? Remove Ads Content creator Ben Sweeney orchestrated full scene Tired of too many ads? Remove Ads Some onlookers were hopeful People in Midtown, New York City (NYC), were left amazed and flabbergasted after the humanoid marched through Midtown. While strolling on roads, the humanoid was seen grabbing hot dogs, trying on sneakers, and catching attention in a wild promo stunt. The KOID-branded bot, priced around $100,000, was rolled out last week by global asset management firm KraneShares to promote its Global Humanoid and Embodied Intelligence Index ETF, which launched in June after the bot rang the Nasdaq opening a global asset management firm, introduced the KOID-branded bot in July 2025 for about $100,000. It was launched to promote their Global Humanoid and Embodied Intelligence Index ETF, which started in June, 2025 after the bot rang the Nasdaq opening Dube, head of marketing at KraneShares, said, 'I feel like I was witnessing firsthand . . . the first lightbulb or the first car,' as quoted by the New York Post. 'People were amazed. Some people were terrified. It was a major mixed bag of reactions,' he added. During the stunt, the bot walked down Fifth Avenue, stopped for selfies, and strolled into a Hoka store, where surprised staff even helped it try on creator Ben Sweeney set up the entire scene, filming for the @NewYorkers social account and chatting with people on the street. The videos went viral online, with some getting over 100,000 likes.'To mess with humanity . . . y'all gotta stop. Satan, I rebuke you to hell,' one man on the street shouted, according to New York Post. 'How much am I getting paid, and how much is the robot getting paid?' another asked. 'It's going to happen,' a woman said when asked about a potential robot takeover.A blind man called the tech 'wonderful,' noting it could help people who can't have guide dogs due to allergies or other limitations. 'I mean, I would love for it to clean my house,' another passerby said. KOID, developed by Chinese robotics company Unitree and distributed by RoboStore in Long Island, is powered by Stanford's OpenMind bot was controlled remotely during its Fifth Avenue walk, but according to Dube, it's fully programmable and already in use in research labs and universities. Since launch, KraneShares says the ETF has drawn in $28 million. According to the NY Post, the Morgan Stanley Global Humanoid Model projects that there could be 1 billion humanoids and $5 trillion in annual revenue by 2050.
